/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

JASPER THERAPEUTICS INC

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$1.6 0.0443(4.43%) JSPR at 04 Dec 2025 04:36 PM Biotechnology
Lowest Today 1.4
Highest Today 1.66
Today’s Open 1.5
Prev. Close 1.58
52 Week High 23.89
52 Week Low 1.39
Day’s Range: Low 1.4 High 1.66
52-Week Range: Low 1.39 High 23.89
1 day return -
1 Week return -9.89
1 month return -9.64
3 month return -38.57
6 month return -72.62
1 year return -92.91
3 year return -73.5
5 year return -98.34
10 year return -

Institutional Holdings

Soleus Capital Management, L.P. 9.19

Velan Capital Investment Management LP 8.82

The Carlyle Group Inc 6.56

Qiming U.S. Ventures Management, LLC 5.72

Morgan Stanley - Brokerage Accounts 4.74

T. Rowe Price Investment Management,Inc. 4.33

Kingdon Capital Management LLC 4.21

Vanguard Group Inc 3.84

Integral Health Asset Management, LLC 3.63

Rock Springs Capital Management LP 3.35

Franklin Resources Inc 3.29

UBS Group AG 2.56

Vanguard Total Stock Mkt Idx Inv 2.54

Citadel Advisors Llc 2.53

Bank of America Corp 1.81

Goldman Sachs Group Inc 1.54

T. Rowe Price U.S. SC Value Eq Tr-D 1.52

BlackRock Inc 1.39

DWS ESG Biotech LC 0.98

Deutsche Bank AG 0.98

Bank of Montreal 0.97

BMO Capital Markets Corp. 0.97

Lion Point Capital, LP 0.90

Vanguard Institutional Extnd Mkt Idx Tr 0.78

Fidelity Extended Market Index 0.38

iShares Micro-Cap ETF 0.18

Extended Equity Market Fund K 0.16

Fidelity Total Market Index 0.13

Fidelity Series Total Market Index 0.10

T. Rowe Price U.S. Equities Tr 0.10

Spartan Extended Market Index Pool F 0.09

Northern Trust Extended Eq Market Idx 0.08

NT Ext Equity Mkt Idx Fd - L 0.08

Fidelity VIP Disciplined Small Cap Init 0.07

DFA US Small Cap I 0.07

Fidelity Nasdaq Composite Index 0.06

NT Ext Equity Mkt Idx Fd - NL 0.06

Vanguard Balanced Index Inv 0.05

AQR Small Cap Momentum Style I 0.05

Spartan Total Market Index Pool G 0.05

Market Status

Strong Buy: 7

Buy: 4

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 44.21 M

PB Ratio 4.1598

PE Ratio 0.0

Enterprise Value -1.06 M

Total Assets 79.90 M

Volume 3809494

Company Financials

Annual Revenue FY23:0 0.0M, FY22:13511000 13.5M, FY21:6196000 6.2M, FY20:0 0.0M, FY19:null 0.0M

Annual Profit FY23:null 0.0M, FY22:13511000 13.5M, FY21:6196000 6.2M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-61095000 -61.1M, FY22:-24174000 -24.2M, FY21:-23984000 -24.0M, FY20:-31669000 -31.7M, FY19:null 0.0M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:null 0.0M, Q2/2025:-258000 -0.3M, Q1/2025:-279000 -0.3M, Q3/2024:null 0.0M, Q2/2024:-299000 -0.3M

Quarterly Net worth Q3/2025:-18736000 -18.7M, Q2/2025:-26723000 -26.7M, Q1/2025:-21241000 -21.2M, Q3/2024:-18637000 -18.6M, Q2/2024:-14583000 -14.6M

Fund house & investment objective

Company Information Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. Jasper Therapeutics, Inc. was founded in 2018 and is based in Redwood City, California.

Organisation Biotechnology

Employees 27

Industry Biotechnology

CEO Mr. Ronald A. Martell

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow